Gamida Cell Ltd.’s Omisirge (omidubicel-onlv) will be the first substantially modified cord blood-based stem cell graft source for allogeneic hematopoietic progenitor cell transplantation following FDA approval, using the Israeli company’s stem cell expansion and enhancement technology to improve clinical outcomes with umbilical cord blood grafts – and in doing so, address a significant health inequity.
The FDA approved Omisirge on 17 April 2023 for adult and pediatric patients 12 years and older with blood cancers who are planned for umbilical cord blood transplantation following myeloablative conditioning